Company Filing History:
Years Active: 1977-1981
Title: Richard S. Schneider: Innovator in Immunoassay Reagents
Introduction
Richard S. Schneider, based in Saratoga, California, is a notable inventor with a total of four patents to his name. His work focuses primarily on the development of advanced reagents for immunoassays, particularly in the detection of benzodiazepines and cocaine metabolites. His contributions to the field have significantly enhanced diagnostic methodologies.
Latest Patents
One of Schneider's latest patents involves the synthesis of oxazepam derivatives designed for use as immunoassay reagents. These compounds are specifically tailored for the preparation of reagents that operate effectively in immunoassays for benzodiazepines, especially focusing on their urinary metabolites. The innovation centers around non-oxo-carbonyl derivatives that are conjugated to the 3-position of the benzodiazepine, which are subsequently attached to antigenic polypeptides. This process facilitates the production of antibodies capable of detecting various benzodiazepine drugs through urine analysis.
Additionally, Schneider's research has led to the development of non-oxo-carbonyl compounds related to benzoyl ecgonine and cocaine. These derivatives can be conjugated with other substances to create reagents applicable in diverse immunoassay techniques. Notably, carboxy or imidoyl derivatives are engineered for conjugation with antigens, aiding in the preparation of antibodies specific to cocaine. This innovation supports both qualitative and quantitative tests for the presence of cocaine.
Career Highlights
Schneider's professional journey is marked by his association with Syva Company, where he continues to push the boundaries of immunoassay technology. His inventive contributions have not only advanced the science of drug detection but have also demonstrated the practical application of his innovations in clinical settings.
Collaborations
Throughout his career, Richard S. Schneider has collaborated with esteemed colleagues such as Steven J. Gould and Michael J. Soffer. These partnerships have fostered an environment of innovation and have facilitated the successful execution of groundbreaking research.
Conclusion
Richard S. Schneider stands out as a prominent inventor in the realm of immunoassay reagents. His patents reflect his dedication to advancing the diagnostic field, with significant implications for drug detection and public health. As he continues his work at Syva Company, the impact of his innovations is expected to grow, showcasing the vital role of inventors in enhancing modern medical technologies.